An essential primer for understanding the role of topical hemostats, surgical sealants, and adhesives for maintaining hemostasis

Pharmacotherapy

Volumn 33, Issue 9, 2013, Pages 935-955

  Gabay, Michael ^a   Boucher, Bradley A ^b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Gelatin; Hemostasis; Pharmacist's role; Pharmacy and therapeutics committee; Sealant; Surgical bleeding; Thrombin; Topical hemostat

Indexed keywords

COLLAGEN; CYANOACRYLIC ACID OCTYL ESTER; FIBRIN GLUE; GELATIN SPONGE; GELFOAM; HEMOSTATIC AGENT; MICROCRYSTALLINE COLLAGEN; OXIDIZED REGENERATED CELLULOSE; SURGICAL GLUE; THROMBIN;

ADHESION BARRIER GEL; ALLERGIC REACTION; BLEEDING; BLOOD CLOTTING; CLINICAL EFFECTIVENESS; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DISEASE CONTROL; GAS EMBOLISM; HEMOSTASIS; HUMAN; LIQUORRHEA; NERVE INJURY; OUTCOME ASSESSMENT; PARALYSIS; PATIENT SAFETY; PRODUCT SAFETY; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SURGICAL INFECTION; SURGICAL SPONGE; THROMBOCYTE AGGREGATION; THROMBOSIS; VIRUS TRANSMISSION;

GELATIN; HEMOSTASIS; PHARMACIST'S ROLE; PHARMACY AND THERAPEUTICS COMMITTEE; SEALANT; SURGICAL BLEEDING; THROMBIN; TOPICAL HEMOSTAT;

ADHESIVES; ADMINISTRATION, TOPICAL; FIBRIN TISSUE ADHESIVE; HEMOSTASIS; HEMOSTATICS; HUMANS; POLYETHYLENE GLYCOLS; THROMBIN;

EID: 84885363323     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1002/phar.1291     Document Type: Review

References (107)

1. National Center for Health Statistics. Centers for Disease Control and Prevention. National Hospital Discharge Survey, 2009. Available from http://www.cdc.gov/nchs/fastats/insurg. htm. Accessed November 16, 2012
2. Pandey S, Vyas GN. Adverse effects of plasma transfusion. Transfusion 2012;52(suppl 1):65S-79S
3. Vamvakas EC, Blajchman MA. Transfusion-related mortality: the ongoing risks of allogeneic blood transfusion and the available strategies for their prevention. Blood 2009;113: 3406-17
4. Boucher BA, Traub O. Achieving hemostasis in the surgical field. Pharmacotherapy 2009;29:2S-7S
5. Glusa E. Vascular effects of thrombin. Semin Thromb Hemost 1992;18:296-304
6. Pfizer. Gelfoam Absorbable Gelatin Sponge, prescribing information. New York, NY; 2012
7. Johnson & Johnson Wound Management/Ethicon, Inc. Surgifoam Absorbable Gelatin Sponge, prescribing information. Somerville, NJ; 2008
8. Zirna H, Keating SE, DeVincentis AF. Topical hemostatic agents to reduce bleeding from cancellous bone surfaces: a comparison of Gelfoam paste and bone wax. J Foot Surg 1987;26:496-500
9. Ragusa R, Faggian G, Rungatscher A, Cugola D, Marcon A, Mazzucco A. Use of gelatin powder added to rifamycin versus bone wax in sternal wound hemostasis after cardiac surgery. Interact Cardiovasc Thorac Surg 2007;6:52-5
10. Council on Pharmacy and Chemistry. Council on pharmacy and chemistry: absorbable gelatin sponge - new and nonofficial remedies. JAMA 1947;135:921
11. Treves N. Prophylaxis of postmammectomy lymphedema by the use of Gelfoam laminated rolls; a preliminary report, with a review of the theories on the etiology of elephantiasis chirurgica and a summary of previous operations for its control. Cancer 1952;5:73-84
12. Rarig HR. Successful use of gelatin foam sponge in surgical restoration of fertility. Am J Obstet Gynecol 1963;86:136
13. Baxter Healthcare Corp. Gelfoam (absorbable gelatin sponge, USP), Gelfoam Plus Hemostasis Kit. Hayward, CA; 2009
14. Johnson & Johnson Wound Management/Ethicon, Inc. Evithrom Thrombin, Topical (human), prescribing information. Somerville, NJ; 2009
15. Oz MC, Cosgrove DM 3rd, Badduke BR, et al. Controlled clinical trial of a novel hemostatic agent in cardiac surgery. The Fusion Matrix Study Group. Ann Thorac Surg 2000;69:1376-82
16. Johnson & Johnson Wound Management/Ethicon, Inc. Surgiflo Hemostatic Matrix Kit, prescribing information. Somerville, NJ; 2011
17. FDA. FDA public health notification: paralysis from absorbable hemostatic agent. April 2, 2004. Available from http:// www.fda.gov/MedicalDevices/Safety/ AlertsandNotices/Public- HealthNotifications/ucm062146.htm. Accessed November 16, 2012
18. Bard, Inc., Davol. Avitene Microfibrillar Collagen Hemostat (MCH) [instructions for use]. Warwick, RI; 2011
19. Bard, Inc., Davol. Avitene Ultrafoam Collagen Sponge [instructions for use]. Warwick, RI; 2011
20. Integra LifeSciences Corporation. Helistat Absorbable Collagen Hemostatic Sponge, prescribing information. Plainsboro, NJ; 2011
21. Integra LifeSciences Corporation. Helitene Absorbable Collagen Hemostatic Agent, prescribing information. Plainsboro, NJ; 2011
22. Johnson & Johnson Wound Management/Ethicon. Instat MCH microfibrillar collagen hemostat, prescribing information. 2010
23. Zucker WH, Mason RG. Ultrastructural aspects of interactions of platelets with microcrystalline collagen. Am J Pathol 1976;82:129-42
24. Zwischenberger JB, Brunston RL Jr, Swann JR, Conti VR. Comparison of two topical collagen-based hemostatic sponges during cardiothoracic procedures. J Invest Surg 1999;12:101-6
25. Johnson & Johnson Wound Management/Ethicon, Inc. Surgicel Original; Surgicel Nu-Knit; Surgicel Fibrillar; Surgicel SNoW Absorbable Hemostats (oxidized regenerated cellulose), prescribing information. Somerville, NJ; 2010
26. . Hanks JB, Kjaergard HK, Hollingsbee DA. A comparison of the haemostatic effect of Vivostat patient-derived fibrin sealant with oxidised cellulose (Surgicel) in multiple surgical procedures. Eur Surg Res 2003;35:439-44
27. Frantz VK. Absorbable cotton, paper and gauze: (oxidized cellulose). Ann Surg 1943;118:116-26
28. Gao HW, Lin CK, Yu CP, Yu MS, Chen A. Oxidized cellulose (Surgicel) granuloma mimicking a primary ovarian tumor. Int J Gynecol Pathol 2002;21:422-3
29. Azmy AF. Oxidized cellulose haemostat mimicking a possible recurrence of neuroblastoma. BJU Int 2001;88:295-6
30. Somani BK, Kasthuri RS, Shave RM, Emtage LA. Surgicel granuloma mimicking a renal tumour. Surgery 2006;139:451
31. Sandhu GS, Elexpuru-Camiruaga JA, Buckley S. Oxidized cellulose (Surgicel) granulomata mimicking tumour recurrence. Br J Neurosurg 1996;10:617-9
32. Kothbauer KF, Jallo GI, Siffert J, Jimenez E, Allen JC, Epstein FJ. Foreign body reaction to hemostatic materials mimicking recurrent brain tumor. Report of three cases. J Neurosurg 2001;95:503-6
33. Agarwal MM, Mandal AK, Agarwal S, et al. Surgicel granuloma: unusual cause of "recurrent" mass lesion after laparoscopic nephron-sparing surgery for renal cell carcinoma. Urology 2010;76:334-5
34. Henry MC, Tashjian DB, Kasowski H, Duncan C, Moss RL. Postoperative paraplegia secondary to the use of oxidized cellulose (Surgicel). J Pediatr Surg 2005;40:E9-11
35. Brodbelt AR, Miles JB, Foy PM, Broome JC. Intraspinal oxidised cellulose (Surgicel) causing delayed paraplegia after thoracotomy - a report of three cases. Ann R Coll Surg Engl 2002;84:97-9
36. Menovsky T, Plazier M, Rasschaert R, Maas AI, Parizel PM, Verbeke S. Massive swelling of Surgicel(R) FibrillarTM hemostat after spinal surgery. Case report and a review of the literature. Minim Invasive Neurosurg 2011;54:257-9
37. Medafor, Inc. Arista AH Absorbable Hemostatic Particles Microporous Polysaccharide Hemosphere (MPH) Technology, prescribing information. Minneapolis, MN: 2008
38. Spotnitz WD, Burks S. State-of-the-art review: hemostats, sealants, and adhesives II: update as well as how and when to use the components of the surgical toolbox. Clin Appl Thromb Hemost 2010;16:497-514
39. Spotnitz WD, Burks S. Hemostats, sealants, and adhesives III: a new update as well as cost and regulatory considerations for components of the surgical toolbox. Transfusion 2012;52:2243-55
40. King Pharmaceuticals Inc. Thrombin-JMI (thrombin, topical USP, bovine origin) package insert. Bristol, TN; 2010
41. ZymoGenetics, Inc. Recothrom Thrombin, Topical (recombinant), prescribing information. Seattle, WA; 2009
42. Kessler CM, Ortel TL. Recent developments in topical thrombins. Thromb Haemost 2009;102:15-24
43. Lawson JH. The clinical use and immunologic impact of thrombin in surgery. Semin Thromb Hemost 2006;32(suppl 1):98-110
44. Doria C, Fischer CP, Wood CG, Li PM, Marra S, Hart J. Phase 3, randomized, double-blind study of plasma-derived human thrombin versus bovine thrombin in achieving hemostasis in patients undergoing surgery. Curr Med Res Opin 2008;24:785-94
45. Chapman WC, Singla N, Genyk Y, et al. A phase 3, randomized, double-blind comparative study of the efficacy and safety of topical recombinant human thrombin and bovine thrombin in surgical hemostasis. J Am Coll Surg 2007;205:256-65
46. Danger of giving topical thrombin intravascularly. ISMP Nurse Advise-ERR 2008;6. Available at www.ismp.org/newsletters/nursing/articles/2008-2003-2001. asp
47. Gershon SK, Chang AC, Purvis WV, Salive M. Misadministration of topical bovine thrombin. JAMA 1999;282:1919
48. Baxter Healthcare Corp. FloSeal Hemostatic Matrix [instructions for use]. Hayward, CA; 2005
49. Nasso G, Piancone F, Bonifazi R, et al. Prospective, randomized clinical trial of the FloSeal matrix sealant in cardiac surgery. Ann Thorac Surg 2009;88:1520-6
50. Richter F, Schnorr D, Deger S, et al. Improvement of hemostasis in open and laparoscopically performed partial nephrectomy using a gelatin matrix-thrombin tissue sealant (FloSeal). Urology 2003;61:73-7
51. Gill IS, Ramani AP, Spaliviero M, et al. Improved hemostasis during laparoscopic partial nephrectomy using gelatin matrix thrombin sealant. Urology 2005;65:463-6
52. Baumann A, Caversaccio M. Hemostasis in endoscopic sinus surgery using a specific gelatin-thrombin based agent (Flo- Seal). Rhinology 2003;41:244-9
53. Woodworth BA, Chandra RK, LeBenger JD, Ilie B, Schlosser RJ. A gelatin-thrombin matrix for hemostasis after endoscopic sinus surgery. Am J Otolaryngol 2009;30:49-53
54. Baxter Healthcare Corp. TisseelTM [Fibrin Sealant] Frozen Solution and Lyophilized Powder for Solution for Topical Application, instructions for use. Hayward, CA; 2010
55. Johnson & Johnson Wound Management/Ethicon, Inc. Evicel Fibrin Sealant (Human), Frozen Solutions of BAC2 (fibrinogen) and Thrombin. Somerville, NJ; 2009
56. Baxter Healthcare Corp. TachoSil (Absorbable Fibrin Sealant Patch). Westlake Village, CA; 2010
57. Ethicon, Inc. EVARREST Fibrin Sealant Patch [prescribing information]. Somerville, NJ; 2012
58. Jackson MR. Fibrin sealants in surgical practice: an overview. Am J Surg 2001;182:1S-7S
59. Lew WK, Weaver FA. Clinical use of topical thrombin as a surgical hemostat. Biologics 2008;2:593-9
60. Rousou J, Levitsky S, Gonzalez-Lavin L, et al. Randomized clinical trial of fibrin sealant in patients undergoing resternotomy or reoperation after cardiac operations. A multicenter study. J Thorac Cardiovasc Surg 1989;97:194-203
61. Lowe J, Luber J, Levitsky S, et al. Evaluation of the topical hemostatic efficacy and safety of TISSEEL VH S/D fibrin sealant compared with currently licensed TISSEEL VH in patients undergoing cardiac surgery: a phase 3, randomized, doubleblind clinical study. J Cardiovasc Surg (Torino) 2007;48:323-31
62. Schwartz M, Madariaga J, Hirose R, et al. Comparison of a new fibrin sealant with standard topical hemostatic agents. Arch Surg 2004;139:1148-54
63. Maisano F, Kjaergard HK, Bauernschmitt R, et al. TachoSil surgical patch versus conventional haemostatic fleece material for control of bleeding in cardiovascular surgery: a randomised controlled trial. Eur J Cardiothorac Surg 2009;36:708-14
64. US Department of Health and Human Services. Cryoseal FS System [instructions for use]. Available from http://www.fda. gov/downloads/ BiologicsBloodVaccines/BloodBloodProducts/ ApprovedProducts/ PremarketApprovalsPMAs/ucm093321.pdf. Accessed November 16, 2012
65. SpecialChem. ThermoGenesis Expands European Distribution of CryoSeal Fibrin Sealant (FS) System and Thrombin Processing DeviceTM (TPD) to Czech Republic, Slovakia and Greece [press release]. Rancho Cordova, CA; June 14, 2006
66. Orthovita, Inc. Vitagel Surgical Hemostat [instructions for use]. Malvern, PA; 2007
67. CoStasis Multi-Center Collaborative Writing Committee. A novel collagen-based composite offers effective hemostasis for multiple surgical indications: results of a randomized controlled trial. Surgery 2001;129:445-50
68. Chapman WC, Clavien PA, Fung J, Khanna A, Bonham A. Effective control of hepatic bleeding with a novel collagenbased composite combined with autologous plasma: results of a randomized controlled trial. Arch Surg 2000;135:1200-4; discussion 1205
69. Achneck HE, Sileshi B, Jamiolkowski RM, Albala DM, Shapiro ML, Lawson JH. A comprehensive review of topical hemostatic agents: efficacy and recommendations for use. Ann Surg 2010;251:217-28
70. Baxter Healthcare Corp. TachoSil [Absorbable Fibrin Sealant Patch]. Westlake Village, CA; Available from http://www.ecomm.baxter.com/ecatalog/ browseCatalog.do?lid=10001&hid =10001&cid=10016&key= b2978a88d06e96f413a0a2e2bc3cf5&pid=592063. Accessed February 4, 2013
71. Baxter Healthcare Corp. Coseal Surgical Sealant [instructions for use]. Hayward, CA; 2009
72. Confluent Surgical, Inc. DuraSeal Dural Sealant System [instructions for use]. Waltham, MA; 2010
73. Neomend, Inc. Progel Pleural Air Leak Sealant [instructions for use]. Irvine, CA; 2011
74. Elefteriades JA. How I do it: utilization of high-pressure sealants in aortic reconstruction. J Cardiothorac Surg 2009;4:27
75. Glickman M, Gheissari A, Money S, Martin J, Ballard JL. A polymeric sealant inhibits anastomotic suture hole bleeding more rapidly than Gelfoam/thrombin: results of a randomized controlled trial. Arch Surg 2002;137:326-31; discussion 332
76. Cosgrove GR, Delashaw JB, Grotenhuis JA, et al. Safety and efficacy of a novel polyethylene glycol hydrogel sealant for watertight dural repair. J Neurosurg 2007;106:52-8
77. Osbun JW, Ellenbogen RG, Chesnut RM, et al. A multicenter, single-blind, prospective randomized trial to evaluate the safety of a polyethylene glycol hydrogel (DuraSeal Dural Sealant System) as a dural sealant in cranial surgery. World Neurosurg 2012;78:498-504
78. Kim KD, Wright NM. Polyethylene glycol hydrogel spinal sealant (DuraSeal Spinal Sealant) as an adjunct to sutured dural repair in the spine: results of a prospective, multicenter, randomized controlled study. Spine (Phila Pa 1976) 2011;36:1906-12
79. Allen MS, Wood DE, Hawkinson RW, et al. Prospective randomized study evaluating a biodegradable polymeric sealant for sealing intraoperative air leaks that occur during pulmonary resection. Ann Thorac Surg 2004;77:1792-801
80. Toriumi DM, Bagal AA. Cyanoacrylate tissue adhesives for skin closure in the outpatient setting. Otolaryngol Clin North Am 2002;35:103-18, vi-vii
81. Farion KJ, Osmond MH, Hartling L, et al. Tissue adhesives for traumatic lacerations: a systematic review of randomized controlled trials. Acad Emerg Med 2003;10:110-8
82. Coulthard P, Esposito M, Worthington HV, van der Elst M, van Waes OJ, Darcey J. Tissue adhesives for closure of surgical incisions. Cochrane Database Syst Rev 2010;(5): CD004287
83. Ethicon, LLC. Dermabond Advanced Adhesive [instructions for use]. Lorenzo, Puerto, Rico; 2011
84. Covidien AG. Indermil Tissue Adhesive package insert. Mansfield, MA; 2011
85. TissueSeal, LLC. Histoacryl and Histoacryl Blue Topical Skin Adhesive package insert.. Ann Arbor, MI; 2008
86. Mertz PM, Davis SC, Cazzaniga AL, Drosou A, Eaglstein WH. Barrier and antibacterial properties of 2-octyl cyanoacrylate- derived wound treatment films. J Cutan Med Surg 2003;7:1-6
87. Narang U, Mainwaring L, Spath G, Barefoot J. In-vitro analysis for microbial barrier properties of 2-octyl cyanoacrylatederived wound treatment films. J Cutan Med Surg 2003;7:13-9
88. Bhende S, Rothenburger S, Spangler DJ, Dito M. In vitro assessment of microbial barrier properties of Dermabond topical skin adhesive. Surg Infect (Larchmt) 2002;3:251-7
89. CryoLife, Inc. BioGlue Surgical Adhesive Syringe [instructions for use]. Kennesaw, GA; 2010
90. Coselli JS, Bavaria JE, Fehrenbacher J, Stowe CL, Macheers SK, Gundry SR. Prospective randomized study of a proteinbased tissue adhesive used as a hemostatic and structural adjunct in cardiac and vascular anastomotic repair procedures. J Am Coll Surg 2003;197:243-52
91. Everts PA, Devilee RJ, Brown Mahoney C, et al. Platelet gel and fibrin sealant reduce allogeneic blood transfusions in total knee arthroplasty. Acta Anaesthesiol Scand 2006;50:593-9
92. Levy O, Martinowitz U, Oran A, Tauber C, Horoszowski H. The use of fibrin tissue adhesive to reduce blood loss and the need for blood transfusion after total knee arthroplasty. A prospective, randomized, multicenter study. J Bone Joint Surg Am 1999;81:1580-8
93. Tyler LS, Cole SW, May JR, et al. ASHP guidelines on the pharmacy and therapeutics committee and the formulary system. Am J Health Syst Pharm 2008;65:1272-83
94. Joint Commission Medication Management Standards. Available from http://www.jointcommission.org/standards-information/ npsgs.aspx. Accessed January 4, 2013
95. Centers for Medicare & Medicaid Services Conditions of Participation. State Operations Manual. Appendix A - Survey Protocol, Regulations and Interpretive Guidelines for Hospitals. Available from http://www.cms.gov/ Regulations-and-Guidance/ Guidance/Manuals/downloads/som107ap-a-hospitals.pdf. Accessed January 4, 2013
96. Kiani S, Brecht ML, Lovinger K, Poston RS. Managing portsite bleeding during less invasive coronary artery bypass grafting. Heart Surg Forum 2012;15:E272-6
97. Anegg U, Rychlik R, Smolle-Juttner F. Do the benefits of shorter hospital stay associated with the use of fleece-bound sealing outweigh the cost of the materials? Interact Cardiovasc Thorac Surg 2008;7:292-6; discussion 226
98. Shander A, Hofmann A, Gombotz H, Theusinger OM, Spahn DR. Estimating the cost of blood: past, present, and future directions. Best Pract Res Clin Anaesthesiol 2007;21:271-89
99. Sullivan MT, Cotten R, Read EJ, Wallace EL. Blood collection and transfusion in the United States in 2001. Transfusion 2007;47:385-94
100. Engoren M, Arslanian-Engoren C, Steckel D, Neihardt J, Fenn-Buderer N. Cost, outcome, and functional status in octogenarians and septuagenarians after cardiac surgery. Chest 2002;122:1309-15
101. Hannon TJ, Gjerde KP. The contemporary economics of transfusions. In: Spiess BD, Spence RK, Shader A, eds. Perioperative transfusion medicine. Philadelphia, PA: Lippincott Williams & Wilkins, 2006. 13-38
102. Maxon MS, Engley G, Wisont KD, Russell T. Economic impact of immune-mediated coagulopathy in the postoperative patient [abstract 159]. Presented at the 2009 Annual Meeting of the American College of Clinical Pharmacy; October 18-21, 2009; Anaheim, CA
103. Stokes ME, Ye X, Shah M, et al. Impact of bleeding-related complications and/or blood product transfusions on hospital costs in inpatient surgical patients. BMC Health Serv Res 2011;11:135
104. Shander A, Hofmann A, Ozawa S, Theusinger OM, Gombotz H, Spahn DR. Activity-based costs of blood transfusions in surgical patients at four hospitals. Transfusion 2010;50:75365
105. Goodnough LT, Bodner MS, Martin JW. Blood transfusion and blood conservation: cost and utilization issues. Am J Med Qual 1994;9:172-83
106. Karimi M, Florentino-Pineda I, Weatherred T, et al. Blood conservation operations in pediatric cardiac patients. A paradigm shift of blood use. Ann Thorac Surg 2013;95:962-7
107. Shander A, Javidroozi M, Perelman S, Puzio T, Lobel G. From bloodless surgery to patient blood management. Mt Sinai J Med 2012;79:56-65.